|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-12-15
|
|
pubmed:abstractText |
Chemoradiation based on cisplatin is the standard treatment for locally advanced cervical carcinoma; however, the optimal scheduling and dosing have still not been established. This study was conducted to determine the maximum-tolerated dose (MTD) of cisplatin for daily administration during pelvic radiotherapy (RT).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
96
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
194-7
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15589600-Adult,
pubmed-meshheading:15589600-Aged,
pubmed-meshheading:15589600-Antineoplastic Agents,
pubmed-meshheading:15589600-Cisplatin,
pubmed-meshheading:15589600-Combined Modality Therapy,
pubmed-meshheading:15589600-Dose-Response Relationship, Drug,
pubmed-meshheading:15589600-Drug Administration Schedule,
pubmed-meshheading:15589600-Female,
pubmed-meshheading:15589600-Humans,
pubmed-meshheading:15589600-Middle Aged,
pubmed-meshheading:15589600-Uterine Cervical Neoplasms
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase I study of daily cisplatin and concurrent radiotherapy in patients with cervical carcinoma.
|
|
pubmed:affiliation |
Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan. makira-cib@umin.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
